Clinical trials
HER2 Positive Breast Carcinoma clinical trials
Below are recruiting her2 positive breast carcinoma clinical trials, each written for real people, not researchers. We’re tracking 282 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07285382RecruitingPhase 2
Dalpiciclib plus letrozole for advanced HR+ HER2- breast cancer
This trial tests a new combination of two drugs (dalpiciclib and letrozole) as a first treatment for advanced breast cancer that is hormone receptor positive and HER2 negative. It aims to find the best dose to slow or stop cancer growth.
Dalian, LiaoningAges 18–75 - NCT07276880RecruitingPhase 2
Chemo, immunotherapy, and radiation for lymph node-positive triple-negative breast cancer
This trial tests a combination of chemotherapy, the immunotherapy drug pembrolizumab, and low or high-dose radiation before surgery for people with triple-negative breast cancer that has spread to the lymph nodes. The goal is to see if this approach can improve treatment outcomes.
Chapel Hill, North CarolinaAges 18 years+ - NCT05955170RecruitingPhase 2
Tucatinib plus oral chemo and trastuzumab for metastatic HER2+ breast cancer
This Phase 2 trial studies tucatinib combined with oral etoposide and trastuzumab in people with metastatic HER2-positive breast cancer, aiming to slow cancer growth. You may be eligible if you previously had progression on a similar HER2-targeted treatment or cannot take capecitabine for medical reasons.
Clermont-Ferrand, Clermont FerrandAges 18 years+ - NCT07222215RecruitingPhase 2
Capacitabine with or without elacestrant for ER+ breast cancer
This trial tests if adding a new oral targeted therapy (elacestrant) to standard chemotherapy (capecitabine) works better than chemotherapy alone for people with a specific type of advanced breast cancer that is hormone-sensitive (ER-positive) and has stopped responding to hormone therapy.
Boston, MassachusettsAges 18 years+ - NCT05535413RecruitingPhase 1/Phase 2
UTD1 plus capecitabine for HER2-negative breast cancer brain mets
This trial tests whether adding a study drug called UTD1 to capecitabine can shrink or control breast cancer that has spread to the brain. It’s for people with HER2-negative metastatic breast cancer who have brain metastases and meet specific safety and lab requirements.
ChangshaAges 18–70 - NCT07191717RecruitingPhase 2
Imlunestrant and abemaciclib for early ER+ breast cancer
This trial tests whether adding two targeted drugs, imlunestrant and abemaciclib, to your usual hormone therapy can lower the chance of your breast cancer coming back. It is for people with early-stage ER+ breast cancer who have no signs of cancer on scans but have tiny amounts of tumor DNA in their blood (called ctDNA).
Los Angeles, CaliforniaAges 18 years+ - NCT07182721RecruitingPhase 2
Study of SKB264 plus Inetetamab for advanced HER2+ breast cancer after T-DXd
This trial is testing a combination of two targeted therapies, SKB264 and Inetetamab, for people with advanced HER2-positive breast cancer that has kept growing after treatment with T-DXd and other HER2-targeted therapies. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT06207734RecruitingPhase 2
Stopping CDK4/6 inhibitors in advanced breast cancer
This trial looks at what happens when women with advanced hormone-positive, HER2-negative breast cancer stop taking a CDK4/6 inhibitor after at least a year of successful treatment. The goal is to see if it's safe to take a break from the CDK4/6 inhibitor while continuing hormone therapy alone.
BerlinAges 18 years+ - NCT07152782RecruitingPhase 2
T-DXd with or without neratinib for HER2+ breast cancer brain metastases
This trial tests whether adding neratinib to T-DXd (trastuzumab deruxtecan) works better than T-DXd alone for women with HER2-positive breast cancer that has spread to the brain. It is for those who have not had these specific drugs before.
ShanghaiAges 18–70 - NCT07112053RecruitingPhase 2
Vaccine with hormone therapy or chemo for advanced breast cancer
This trial tests a vaccine (STEMVAC) given with your standard hormone therapy or chemotherapy. It is for people with advanced hormone receptor-positive, HER2-negative breast cancer who are already on certain treatments. The goal is to see if adding the vaccine can help control the cancer better.
Seattle, WashingtonAges 18 years+ - NCT07100600RecruitingPhase 2
Targeted drug with or without radiation for HER2-positive breast cancer brain tumors
This trial tests whether adding radiation therapy to a targeted cancer drug (trastuzumab rezetecan) is better than the drug alone for women with HER2-positive breast cancer that has spread to the brain. If you have untreated brain tumors from this type of breast cancer, this study aims to find the best way to stop them from growing.
Zhengzhou, HenanAges 18 years+ - NCT07102381RecruitingPhase 2
Zanidatamab plus chemo before surgery for HER2+ breast cancer
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
Long Beach, CaliforniaAges 18 years+ - NCT07085767RecruitingPhase 3
Palazestrant and ribociclib for first-line advanced breast cancer
This trial tests a new drug (palazestrant) combined with ribociclib for people with a common type of advanced breast cancer that is estrogen receptor-positive and HER2-negative. You may qualify if you haven't had treatment for advanced disease and your cancer has either just been found or came back long after completing hormone therapy.
Hot Springs, ArkansasAges 18 years+ - NCT07095023Recruiting
Oral chemo and targeted therapy before breast cancer surgery
This trial tests a combination of an oral chemotherapy pill (paclitaxel) with two targeted antibodies (pertuzumab and trastuzumab) given before surgery for HER2-positive breast cancer. The goal is to shrink the tumor and make surgery more effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07081555RecruitingPhase 1
Testing a new radioactive drug for HER2-positive advanced breast cancer
This trial tests a new radioactive drug, [177Lu]Lu-ABY-271, to see how safe it is and where it goes in the body. It is for people with HER2-positive breast cancer that has spread and cannot be removed by surgery.
GothenburgAges 18 years+ - NCT07065435RecruitingPhase 2
RC48 with Avastin or Pyrotinib for HER2+ breast cancer after T-DXd
This trial tests a new combination of drugs (RC48 plus either Avastin or Pyrotinib) for people with HER2-positive breast cancer that has spread and has stopped responding to the drug T-DXd. The goal is to see if these combinations can help shrink tumors and control the cancer longer.
Nanjing, JiangsuAges 18–75 - NCT07057427RecruitingPhase 3
Nab-paclitaxel vs TCbHP for HER2-positive early breast cancer
This trial compares two different drug combinations given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see which combination works better and has fewer side effects.
Zhengzhou, HenanAges 18–70 - NCT07043725RecruitingPhase 3
Neoadjuvant TQB2102 for HER2-positive breast cancer
This trial tests a new drug called TQB2102 given before surgery for HER2-positive breast cancer. The goal is to see if it can shrink the tumor enough to allow a successful surgery.
Bengbu, AnhuiAges 18–75 - NCT07023861Enrolling by invitationEarly Phase 1
New imaging test for HER2-positive cancers
This trial tests a new imaging method that uses a radioactive tracer to find HER2-positive cancer cells in the body. It may help doctors see tumors more clearly in people with stomach, breast, or bladder cancer.
Wuxi, JiangsuAges 15–75 - NCT07030569Recruiting
Predicting treatment response in metastatic breast cancer
This trial studies how well CT and PET scans can predict if a certain type of breast cancer will respond to a targeted treatment. It focuses on women who had a biopsy of the liver, lung, or chest lining after the cancer spread.
MilanAges Any age - NCT07014410RecruitingPhase 2
Pyrotinib, dalpiciclib, and letrozole for advanced breast cancer
This trial tests a combination of three targeted drugs for a type of advanced breast cancer that is both ER-positive and HER2-positive. The goal is to see if adding these two new drugs to standard hormone therapy can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT06992882RecruitingPhase 3
Comparing two chemo regimens with Herceptin for early breast cancer
This trial tests if taking oral chemotherapy pills with trastuzumab (Herceptin) works as well as IV chemo (paclitaxel) with Herceptin after surgery for HER2-positive, lymph node-negative early breast cancer. It aims to find a more convenient treatment option.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06970912RecruitingPhase 2
ctDNA-Guided Reduced Chemo in HR+/HER2- Breast Cancer
This study is testing whether using a ctDNA blood test can help doctors decide if patients with hormone receptor-positive, HER2-negative breast cancer can safely receive less intensive chemotherapy after surgery. The goal is to reduce side effects while still preventing the cancer from coming back.
Beijing, Beijing MunicipalityAges 18–75 - NCT06949410RecruitingPhase 1
HER2 vaccine study for high-risk breast cancer
This trial tests a vaccine designed to help the immune system fight remaining HER2-positive breast cancer cells after standard treatment. It is for people who have completed at least six months of HER2-targeted therapy and still have a high risk of the cancer coming back.
Indianapolis, IndianaAges 18 years+
Hear when a new HER2 Positive Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2 positive breast carcinoma?
- Yes. Clin2 currently lists 282 recruiting her2 positive breast carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2 positive breast carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2 positive breast carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.